Drospirenone
Brand names: Slynd (POP), Yasmin (with EE), Yaz (with EE), Eloine (with EE), Lucette (with EE)
Drospirenone is a progestogen with anti-mineralocorticoid and anti-androgenic activity, used in combined hormonal contraceptives and as a progestogen-only contraceptive pill.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It provides contraception chiefly by inhibiting ovulation, with additional effects on cervical mucus and the endometrium; its anti-mineralocorticoid action counteracts oestrogen-related fluid retention.
Prescribing in practice
- Because of its anti-mineralocorticoid effect, use caution and consider potassium monitoring when co-prescribed with other potassium-raising drugs, as hyperkalaemia can occur.
- When used in a combined preparation, the standard venous thromboembolism risks and contraindications of combined hormonal contraception apply.
- The progestogen-only drospirenone pill provides an oestrogen-free option with a more forgiving missed-pill window than older progestogen-only pills.
Monitoring
Monitor blood pressure; consider checking serum potassium in women also taking other agents that raise potassium or with relevant renal impairment.
Counselling the patient
- Take the pill regularly as directed and follow missed-pill advice for your specific product.
- Report symptoms of a blood clot such as calf swelling, breathlessness or chest pain promptly.
- Tell your clinician about other medicines, particularly those affecting potassium levels.
Evidence & guidelines
Drospirenone-containing contraceptives are established options within UK contraceptive guidance, with attention to thromboembolic and potassium-related considerations.
Reference: SmPC Slynd / Yasmin / Yaz; FSRH UK MEC 2016 (amended 2019); MHRA Drug Safety Update Feb 2014 (COCs and VTE); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS
- Pre-eclampsia Management · NICE NG133 2019
- Ectopic Pregnancy · NICE CG154 / RCOG GTG 21